• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    34 Stocks Moving In Monday's Mid-Day Session

    4/18/22 12:13:56 PM ET
    $AGRI
    $APCX
    $ARQQ
    $CASA
    Metal Fabrications
    Industrials
    Computer Software: Prepackaged Software
    Technology
    Get the next $AGRI alert in real time by email

    Gainers

    • Casa Systems, Inc. (NASDAQ:CASA) shares climbed 66.3% to $6.47 after the company announced a multi-year contract with Verizon to provide 5G core network functions.
    • Natus Medical Incorporated (NASDAQ:NTUS) gained 28.7% to $33.53 after the company announced it will be acquired by ArchiMed Group for $33.50 per share in cash.
    • Forge Global Holdings, Inc. (NYSE:FRGE) jumped 25% to $16.99. Forge Global Holdings named James H. Herbert, II to its Board of Directors, effective as of April 12.
    • AgriFORCE Growing Systems, Ltd. (NASDAQ:AGRI) shares gained 21.3% to $2.6798.
    • BitNile Holdings, Inc. (NYSE:NILE) rose 17% to $0.6436 following a 5% decline on Thursday.
    • Camber Energy, Inc. (NYSE:CEI) rose 16.7% to $1.0150 after gaining over 5% on Thursday.
    • CEL-SCI Corporation (NYSE:CVM) gained 13% to $3.73.
    • San Juan Basin Royalty Trust (NYSE:SJT) jumped 11.6% to $12.07.
    • MedAvail Holdings, Inc. (NASDAQ:MDVL) shares rose 11.1% to $2.7116 after surging around 70% on Thursday. Ally Bridge Group recently reported a purchase of roughly 21.176 million shares of MedAvail Holdings for an average price of $1.06 per share.
    • Enservco Corporation (NASDAQ:ENSV) jumped 10.5% to $2.9080. Enservco delayed filing of Form 10-K to restate 2021 Form 10-Qs to account for company's utilization of deferred tax liabilities.
    • Tritium DCFC Limited (NASDAQ:DCFC) gained 9.9% to $9.36 after the company announced a multi-year contract with BP for the supply of chargers and related services to support BP's global EV charging network.
    • MedAvail Holdings, Inc. (NASDAQ:MDVL) jumped 9.1% to $2.6615.
    • Hallador Energy Company (NASDAQ:HNRG) gained 8.1% to $5.64.
    • Trevi Therapeutics, Inc. (NASDAQ:TRVI) rose 7.3% to $3.52.


    Don’t forget to check out our premarket coverage here .

    Losers

    • Nektar Therapeutics (NASDAQ:NKTR) shares tumbled 33.9% to $4.0750. Nektar Therapeutics and Bristol Myers Squibb Co jointly decided to end the global clinical development program for bempegaldesleukin in combination with Opdivo. Goldman Sachs downgraded Nektar Therapeutics from Neutral to Sell and announced a $3 price target.
    • Gaucho Group Holdings, Inc. (NASDAQ:VINO) fell 23.9% to $1.8464. Gaucho Group recently reported FY21 revenues of $4.9 million.
    • TG Therapeutics, Inc. (NASDAQ:TGTX) fell 19.6% to $7.12 after the company announced it has voluntarily withdrawn the BLA/sNDA for U2 for the treatment of adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
    • Genius Group Limited (NYSE:GNS) dipped 19.5% to $6.40.
    • UserTesting, Inc. (NYSE:USER) dropped 19.3% to $8.40.
    • Arqit Quantum Inc. (NASDAQ:ARQQ) fell 18.6% to $12.25.
    • AppTech Payments Corp. (NASDAQ:APCX) declined 17.3% to $1.8599.
    • Helbiz, Inc. (NASDAQ:HLBZ) fell 14% to $2.2889.
    • Viracta Therapeutics, Inc. (NASDAQ:VIRX) dipped 12.6% to $3.55.
    • Veru Inc. (NASDAQ:VERU) dropped 12.7% to $13.05.
    • Cardiol Therapeutics Inc. (NASDAQ:CRDL) dropped 12.5% to $1.7910.
    • Mullen Automotive, Inc. (NASDAQ:MULN) shares fell 12.5% to $1.8893. Mullen Automotive plans to start Electric Vehicle battery pack production in its research & development facility in California.
    • DiDi Global Inc. (NYSE:DIDI) fell 12.4% to $2.1550 after the company announced a shareholders meeting to vote on voluntarily delisting the company's American Depositary Shares from the New York Stock Exchange. DiDi Global said its total revenue dropped to 40.8 billion yuan ($6.40 billion) for the quarter ended Dec. 31, 2021, down from 46.7 billion yuan in the year-ago period.
    • WeWork Inc. (NYSE:WE) dipped 11.6% to $5.88.
    • Dada Nexus Limited (NASDAQ:DADA) fell 11.4% to $8.13.
    • Gogoro Inc. (NASDAQ:GGR) dipped 10.3% to $8.88.
    • Indonesia Energy Corporation Limited (NYSE:INDO) fell 10.3% to $23.69 after jumping over 65% on Thursday.
    • Mersana Therapeutics, Inc. (NASDAQ:MRSN) dipped 9.5% to $4.4450. Mersana Therapeutics Director Andrew Hack recently reported the purchase of 598,086 shares at an average price of $4.18/share.
    • HDFC Bank Limited (NYSE:HDB) fell 8.1% to $54.12.
    • The Charles Schwab Corporation (NYSE:SCHW) dropped 8.1% to $76.00 after the company reported worse-than-expected Q1 EPS and sales results.
    Get the next $AGRI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGRI
    $APCX
    $ARQQ
    $CASA

    CompanyDatePrice TargetRatingAnalyst
    Veru Inc.
    $VERU
    12/18/2025$25.00Buy
    Canaccord Genuity
    Forge Global Holdings Inc.
    $FRGE
    12/12/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    Charles Schwab Corporation
    $SCHW
    12/11/2025$119.00Buy
    UBS
    Nektar Therapeutics
    $NKTR
    11/26/2025$102.00Buy
    Citigroup
    Trevi Therapeutics Inc.
    $TRVI
    11/13/2025$13.00Outperform
    Leerink Partners
    Forge Global Holdings Inc.
    $FRGE
    11/7/2025Overweight → Neutral
    Piper Sandler
    TG Therapeutics Inc.
    $TGTX
    10/6/2025$60.00Buy
    H.C. Wainwright
    Charles Schwab Corporation
    $SCHW
    10/3/2025$110.00Outperform
    BMO Capital Markets
    More analyst ratings

    $AGRI
    $APCX
    $ARQQ
    $CASA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Kersten Geert R bought $200,001 worth of shares (38,023 units at $5.26), increasing direct ownership by 46% to 120,815 units (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    1/26/26 8:23:27 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Wesley Charles Ray Iv bought $356,576 worth of shares (20,000 units at $17.83) (SEC Form 4)

    4 - HALLADOR ENERGY CO (0000788965) (Issuer)

    12/19/25 7:07:06 PM ET
    $HNRG
    Coal Mining
    Energy

    Chief Executive Officer Kersten Geert R bought $49,998 worth of shares (8,389 units at $5.96), increasing direct ownership by 11% to 81,794 units (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    12/5/25 8:48:04 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGRI
    $APCX
    $ARQQ
    $CASA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Veru with a new price target

    Canaccord Genuity initiated coverage of Veru with a rating of Buy and set a new price target of $25.00

    12/18/25 9:11:57 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forge Global Holdings downgraded by Citizens JMP

    Citizens JMP downgraded Forge Global Holdings from Mkt Outperform to Mkt Perform

    12/12/25 8:42:26 AM ET
    $FRGE
    Investment Bankers/Brokers/Service
    Finance

    UBS resumed coverage on Charles Schwab with a new price target

    UBS resumed coverage of Charles Schwab with a rating of Buy and set a new price target of $119.00

    12/11/25 9:06:22 AM ET
    $SCHW
    Investment Bankers/Brokers/Service
    Finance

    $AGRI
    $APCX
    $ARQQ
    $CASA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Chairman Schwab Charles R. sold $17,079,953 worth of shares (164,600 units at $103.77) (SEC Form 4)

    4 - SCHWAB CHARLES CORP (0000316709) (Issuer)

    2/5/26 9:24:17 PM ET
    $SCHW
    Investment Bankers/Brokers/Service
    Finance

    Co-Chairman Bettinger Walter W exercised 257,410 shares at a strike of $42.99 and sold $26,778,406 worth of shares (257,410 units at $104.03) (SEC Form 4)

    4 - SCHWAB CHARLES CORP (0000316709) (Issuer)

    2/5/26 7:18:31 PM ET
    $SCHW
    Investment Bankers/Brokers/Service
    Finance

    General Counsel Morgan Peter J. Iii exercised 7,595 shares at a strike of $66.47 and sold $792,796 worth of shares (7,595 units at $104.38) (SEC Form 4)

    4 - SCHWAB CHARLES CORP (0000316709) (Issuer)

    2/3/26 9:40:57 PM ET
    $SCHW
    Investment Bankers/Brokers/Service
    Finance

    $AGRI
    $APCX
    $ARQQ
    $CASA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026

    SAN FRANCISCO, Feb. 9, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on the development of novel immunology therapies, today announced it will host an investor call and live webcast to review topline results from the 36-week maintenance period of the ongoing Phase 2b REZOLVE-AD clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for moderate-to-severe atopic dermatitis on Tuesday, February 10, 2026 at 8:00 am ET / 5:00 am PT.  Conference Call The results will be provided in a mo

    2/9/26 4:15:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schwab Trading Activity Index™: STAX Score Sees Highest Reading Since February 2025

    Schwab clients were net buyers of equities in January, with a net buying surge in the Information Technology sector The Schwab Trading Activity Index™ (STAX) increased to 49.96 in January, up from its score of 48.48 in December. The only index of its kind, the STAX is a proprietary, behavior-based index that analyzes retail investor stock positions and trading activity from Schwab's millions of client accounts to illuminate what investors were actually doing and how they were positioned in the markets each month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260209219779/en/ "After a one-month backtrack in December, Schwab cl

    2/9/26 12:30:00 PM ET
    $SCHW
    Investment Bankers/Brokers/Service
    Finance

    TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis

    A Media Snippet accompanying this announcement is available by clicking on this link. NEW YORK, Feb. 08, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced a collaboration with actress Christina Applegate to help raise awareness of multiple sclerosis (MS) and support meaningful conversations for those living with the disease. Christina Applegate, who has been living with MS for 5 years, will lead the new national disease-awareness initiative designed to elevate the voices of people living with MS, highlight the realities, and explore what comes next, on their own terms. The cornerstone of the campaign is www.NextInMS.com, a new platform developed to support p

    2/8/26 4:17:55 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRI
    $APCX
    $ARQQ
    $CASA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

    Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (SUPPL-11) with active ingredient UBLITUXIMAB-XIIY has changed to 'Approval' on 10/30/2024. Application Category: BLA, Application Number: 761238, Application Classification:

    10/31/24 4:38:40 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

    Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (ORIG-1) with active ingredient UBLITUXIMAB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761238, Application Classification:

    12/28/22 12:54:09 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ENTADFI issued to VERU INC

    Submission status for VERU INC's drug ENTADFI (ORIG-1) with active ingredient FINASTERIDE;TADALAFIL has changed to 'Approval' on 12/09/2021. Application Category: NDA, Application Number: 215423, Application Classification: Type 4 - New Combination

    12/13/21 8:12:46 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRI
    $APCX
    $ARQQ
    $CASA
    SEC Filings

    View All

    SEC Form 424B5 filed by Indonesia Energy Corporation Limited

    424B5 - Indonesia Energy Corp Ltd (0001757840) (Filer)

    2/5/26 4:08:40 PM ET
    $INDO
    Oil & Gas Production
    Energy

    SEC Form SCHEDULE 13G filed by Trevi Therapeutics Inc.

    SCHEDULE 13G - Trevi Therapeutics, Inc. (0001563880) (Subject)

    2/5/26 1:40:12 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by HDFC Bank Limited

    6-K - HDFC BANK LTD (0001144967) (Filer)

    2/4/26 6:01:52 AM ET
    $HDB
    Commercial Banks
    Finance

    $AGRI
    $APCX
    $ARQQ
    $CASA
    Leadership Updates

    Live Leadership Updates

    View All

    Charles Schwab Corporation Announces Executive Transitions

    The Charles Schwab Corporation (NYSE:SCHW) today announced several executive transitions, including two planned retirements and organizational updates. Charles Schwab Bank Leadership Transition Paul Woolway, CEO of Charles Schwab Bank, will retire on July 1, 2026, after more than 16 years with the company. Tyler Woulfe, Managing Director, Banking & Trust Services, will succeed Woolway as President and CEO of Charles Schwab Bank, effective July 1, 2026, and will report to Neesha Hathi, Managing Director, Wealth Advisory and Banking Services. Internal Audit Leadership Transition Mitch Mantua, General Auditor, also retires on July 1, 2026, after a decade of service. Jessica Bramhall, M

    1/29/26 4:15:00 PM ET
    $SCHW
    Investment Bankers/Brokers/Service
    Finance

    Hallador Energy Appoints Barbara Sugg, Former CEO of Southwest Power Pool, to Join Board of Directors

    TERRE HAUTE, Ind., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Hallador Energy Company (NASDAQ:HNRG) ("Hallador" or the "Company") today announced that its Board of Directors (the "Board") has appointed Barbara Sugg to the Board, effective January 1, 2026. Ms. Sugg's appointment follows the resignation of David Hardie from the Board, effective January 1, 2026. With the election of Ms. Sugg, Hallador's Board remains at six total members, five of whom are independent under the Nasdaq listing standards. "On behalf of Hallador, I'd like to thank David for his invaluable contributions to the business over his 35-year tenure," said Brent Bilsland, President and Chief Executive Officer. "At the same time,

    1/6/26 8:00:00 AM ET
    $HNRG
    Coal Mining
    Energy

    Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer

    Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth NEW HAVEN, Conn., Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that David Hastings will assume the role of Chief Financial Officer effective January 6, 2026.  www.trevitherapeutics.com (PRNewsfoto/Trevi

    12/4/25 7:30:00 AM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRI
    $APCX
    $ARQQ
    $CASA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Arqit Quantum Inc.

    SC 13D/A - Arqit Quantum Inc. (0001859690) (Subject)

    12/13/24 8:03:28 PM ET
    $ARQQ
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by Arqit Quantum Inc.

    SC 13D/A - Arqit Quantum Inc. (0001859690) (Subject)

    12/10/24 8:05:26 PM ET
    $ARQQ
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by Enservco Corporation

    SC 13D/A - Enservco Corp (0000319458) (Subject)

    12/10/24 4:00:16 PM ET
    $ENSV
    Oilfield Services/Equipment
    Energy

    $AGRI
    $APCX
    $ARQQ
    $CASA
    Financials

    Live finance-specific insights

    View All

    Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026

    SAN FRANCISCO, Feb. 9, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on the development of novel immunology therapies, today announced it will host an investor call and live webcast to review topline results from the 36-week maintenance period of the ongoing Phase 2b REZOLVE-AD clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for moderate-to-severe atopic dermatitis on Tuesday, February 10, 2026 at 8:00 am ET / 5:00 am PT.  Conference Call The results will be provided in a mo

    2/9/26 4:15:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th

    MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Wednesday, February 11, 2026, at 8:00 a.m. ET to discuss its fiscal 2026 first quarter financial results and to provide a business update. The audio webcast will be accessible under the Home page and Investors page of the Company's website at www.verupharma.com. To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru I

    2/4/26 8:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schwab Declares 19% Increase in Quarterly Common Stock Dividend and Declares Preferred Stock Dividends

    The Board of Directors of The Charles Schwab Corporation at its meeting today declared a 5 cent, or 19%, increase in the regular quarterly cash dividend to $0.32 per common share. The dividend is payable February 27, 2026 to stockholders of record as of the close of business on February 13, 2026. Co-Chairman Walt Bettinger commented, "This dividend increase reflects the Board's confidence in our ability to continue to drive profitable growth through-the-cycle as we advance our ‘Through Clients' Eyes' strategy." In addition, the Board of Directors also declared dividends on the following series of outstanding preferred stock, payable March 2, 2026 to stockholders of record as of the clos

    1/29/26 4:18:00 PM ET
    $SCHW
    Investment Bankers/Brokers/Service
    Finance